Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000935
Chunk: 21

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 21
---
 and Additional VWAP Purchase, respectively, as full payment for such Purchase Shares via wire transfer of
immediately available funds on the third (3rd) Business Day following the Investor’s receipt of the Purchase Shares, if such Purchase
Shares are received by the Investor before 1:00 p.m., Eastern time, or, if such Purchase Shares are received by the Investor after 1:00
p.m., Eastern time, the fourth (4th) Business Day following the Investor’s receipt of the Purchase Shares.

| -9- |

(iii) The
Company shall not issue any fraction of a Depositary Share upon any Fixed Purchase, VWAP Purchase or Additional VWAP Purchase. If the
issuance would result in the issuance of a fraction of a Depositary Share, the Company shall round such fraction of a Depositary Share
up or down to the nearest whole share. All payments made under this Agreement shall be made in lawful currency of the United States of
America by wire transfer of immediately available funds to such account as the Company (or the Investor, as applicable) may from time
to time designate by written notice in accordance with the provisions of this Agreement. Whenever any amount expressed to be due by the
terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the next succeeding day that is
a Business Day.

(e) . The Company shall not be required or permitted to issue, and the Investor shall not be required to
purchase, any Depositary Shares under this Agreement if such issuance would breach or violate the rules or regulations of the Principal
Market. Further, in no event may any applicable New Issuance Price under this Agreement result in a price per Security that would violate
the rules or regulations of the Principal Market, and the Company shall not undertake any transaction that would result in such a violative
New Issuance Price. The Company shall not issue or sell any Depositary Shares pursuant to this Agreement if such issuance or sale would
reasonably be expected to result in a violation of the Securities Act.

(f) . Notwithstanding anything to the contrary contained in this Agreement, the Company shall not issue or sell,
and the Investor shall not purchase or acquire, any Ordinary Shares (including Ordinary Shares represented by Depositary Shares)
under this Agreement which, when aggregated with all other Ordinary Shares (including Ordinary Shares represented by Depositary Shares)
then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d